ATR and small cell lung carcinoma: In a drug screening of lurbinectedin in combination with 43 other agents in SCLC, the top synergistic agent was the ATR inhibitor berzosertib, with a 3.5-fold increase in DNA damage compared to lurbinectedin alone [251].